Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093304 | 1.00 | SCN9A (0.45) | SCN9ASLC22A12 | |
| SCHEMBL9923641 | 0.91 | SCN9A (0.42) | SCN9ASLC22A12 | |
| SCHEMBL319485 | 0.90 | SCN9A (0.45) | SCN9ASLC22A12 | |
| SCHEMBL16109346 | 0.89 | SCN9A (0.48) | SCN9A | |
| SCHEMBL29835235 | 0.89 | SCN9A (0.39) | SCN9ASLC22A12 | |
| SCHEMBL21810730 | 0.89 | SCN9A (0.39) | SCN9ASLC22A12 | |
| SCHEMBL320859 | 0.88 | SCN9A (0.43) | SCN9ASLC22A12 | |
| SCHEMBL1109044 | 0.88 | SCN9A (0.47) | SCN9A | |
| SCHEMBL325911 | 0.87 | SCN9A (0.46) | SCN9A | |
| SCHEMBL1095344 | 0.87 | SCN9A (0.46) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3074402-B1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| EP-3043787-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORP (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004714-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | SCN9A 29/4885SLC22A12 670/4885 |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SLC22A12 999/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | SCN9A 32/4885SLC22A12 706/4885 |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | SCN7A, SCN10A, SCN2A | SCN9A 13/4885SLC22A12 1494/4885 |
| US-20170275275-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN2B | SCN9A 13/4885SLC22A12 1348/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | SCN9A 5/4885SLC22A12 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.